Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…ysis of long-term survival data from phase II and III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(1…
… on Cancer stage IV (8th edition).Results All patients received ipilimumab plus nivolumab. The Eastern Cooperative Oncology Group performa…
…ously evaluated in patients with advanced melanoma treated with nivolumab plus ipilimumab. This analysis compared TFS for nivolumab plus …
…nts received ipilimumab and nivolumab (14/31, 45%), followed by pembrolizumab (9/31, 29%), ipilimumab (4/31, 13%), nivolumab (2/31, 6%) and c…
…licated by cytomegalovirus infection, successfully treated with valganciclovir. A repeat colonoscopy demonstrated complete mucosal healing and…
…ce was among melanoma patients receiving combination therapy of ipilimumab and nivolumab, 19% developed ChILI.Liver injury was not attribu…
… during treatment with PD-1 inhibitors. Eight patients received pembrolizumab (six as monotherapy and two in combination with carboplatin plu…
… trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line set…
…is limitation, we evaluated the efficacy and safety of combined ipilimumab and nivolumab (IPI/NIVO) with subablative radiotherapy (RT) in …
… may predict thyroiditis in patients with melanoma treated with ipilimumab and investigated Polygenic Risk Scores (PRSs) previously report…
…to a diagnosis of thyroid storm. Given his prior treatment with nivolumab and ipilimumab, destructive thyroiditis was initially suspected…
…mic bone marrow metastasis that achieved a complete response to ipilimumab plus nivolumab. Using matched pretreatment and post-treatment b…